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Introduction: Conventionally, QT interval is measured in lead II. There are no data to select
an alternative lead for QT measurement when it cannot be measured in Lead II for any
reason.
Methods and results: We retrospectively analyzed ECGs from 1906 healthy volunteers from
41 phase I studies. QT interval was measured on the median beat in all 12 leads. The mean
difference in QT interval between lead aVR and in Lead II was the least, followed by aVF,
V5, V6 and V4; lead aVL had maximum difference. The T wave was flat (<0.1 mV) in Lead II
in 6.9% of ECGs; it was also flat in 20% of these ECGs (1.4% of all ECGs) in Leads aVR, aVF and
V5.
Conclusions: When QT interval cannot be measured in Lead II, the best alternative leads are
aVR, aVF, V5, V6 and V4 in that sequence. It differs maximally from that in Lead II in Lead
aVL.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction state that QT interval is usually the longest in lead II in indi-TheQT interval is routinelymeasured in 12-lead ECGs to study
cardiac repolarization. Prolongation of the QT interval is
associated with sudden death and malignant ventricular
arrhythmias including torsades de pointes and ventricular
fibrillation.1 Since heart disease, genetic factors, electrolyte
disturbances and drugs may affect the QT interval, serial
measurements of QT interval are often required in clinical
practice. The QT interval is conventionally measured in lead II
for various reasons.1e7 Garson suggests that lead II usually
shows a long single wave rather than discrete T and Uwaves,2
making it easy to measure the QT interval. Camm and Malik72, fax: þ91 22 6695 0159.
om (V. Salvi).
2012, Cardiological Societviduals without any repolarization abnormality.4 Moss et al
used lead II for QT interval measurement in patients in the
congenital long QT syndrome registry of the University of
Rochester.6 Consequently, the cut-off values for the prolonged
QT interval have all been defined using QT measurements in
lead II from patients with congenital long QT syndrome.6
The International Conference on Harmonization of Tech-
nical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) requires all new drugs with systemic
bioavailability to be subjected to a thorough QT/QTc (TQT)
study to evaluate their effects on the QT intervals per the E14
guidance.1 In these thorough QT/QTc (TQT) studies, QTy of India. All rights reserved.
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istration of a study drug or placebo are compared with
pre-dose values.8e10 In a recent review of 21 TQT studies, 14
studies had reported the method of QT measurement; it was
measured in Lead II in 8 studies.11 The ICH E14 guidance also
states that “a consistent approach” should be used in choice of
leads for QTmeasurement for the entire study. This is because
the QT interval in various leads of a 12-lead ECG (QT disper-
sion) can differ by 40 to 60 ms in healthy individuals12 and an
apparent prolongation of the QT interval may be observed
merely because the QT interval was measured in different
leads in serial ECGs from the same subject. However, some-
times the quality of the tracing in lead II may not permit
accurate intervalmeasurement, and the QT intervalmay have
to be measured in another lead. For example, in a TQT study
evaluating the effect of Brivaracetam on the QT interval, QT
interval was measured in lead II in only 35% of cases and was
measured in lead V3 in 14%, Lead III in 10% Lead V4 in and lead
V2 in 9%.13 This raises an important question: which is the
best alternative lead for QT interval measurement? An ideal
alternative lead would be one in which the QT interval is
closest to that measured in Lead II. As there was no published
data on this question, we conducted this study in 1906 healthy
volunteers where QT interval was measured in all 12 leads in
order to find the best alternative to lead II.2. Methods
The present study is a retrospective analysis based on ECGs
from 1906 healthy normal volunteers from 41 phase I studies.
All studies were approved by respective institutional review
boards and used stringent screening methods to select
healthy normal volunteers. ECGswere recorded using a digital
electrocardiograph (Eli 250, Mortara Instrument Inc, Milwau-
kee,WI) with a sampling rate of 1000Hz, speed of 25mm/s and
amplitude of 10 mm/mV and electronically transmitted to the
central laboratory of Quintiles ECG Services,Mumbai, India for
analysis. All ECGs were converted into an FDA compliant XML
(extensible markup language) file format and the various
intervals measured manually by four expert readers using
digital on-screen callipers (CalECG version 2.7, AMPS LLC, NY).
The QT intervals were measured on a representative
median beat in each of the twelve leads. The QT interval was
measured from the onset of the first deflection of the QRS
complex to the intersection of the terminal part of the T wave
with the isoelectric line (the line joining midpoints of the
preceding and following T-P segments). If a U wave inter-
rupted the T wave before it returned to baseline, the QT
interval was measured as the nadir between T and U
waves.14e16 Since there can be considerable intra-reader
variability in QT interval measurement, a set of 100 ECGs
were read twice by all readers to quantify intra-reader vari-
ability. The intra-reader variability for the readers ranged
from 2.7 to 3.2 ms, with a mean of 3.01 ms.
We also measured the T wave amplitude in a median
complex of each lead. As presence of a flat T wave (T wave
amplitude <1 mm or 0.1 mV) can lead to increased measure-
ment variability and is often used as a criterion to select
another lead for QT measurement,16,17 analysis was alsoperformed after excluding data from leads in which T wave
amplitude was <1 mm. As amplitude of the T wave depends
on its axis, frontal plane T wave axis was also noted for each
ECG.
2.1. Statistical methods
Differences between QT interval in each lead and that in Lead
II were compared using the paired t test. Adjustment for
multiplicity of comparisons was made using the Bonferroni
correction; a ¼ 0.005 was used as a cut-off for statistical
significance. The actual difference in QT interval measure-
ments in each of the 11 leads and that in Lead II (with the
positive or negative sign) as well as absolute difference (i.e.
without the positive or negative sign) was obtained. All eleven
leads were then ranked such that the lead with the least
absolute difference was ranked 1 and the lead with the
maximum difference was ranked 11.3. Results
The QT interval in lead II in 1906 normal healthy subjects was
391.7 þ 34.6 ms (mean þ SD). When the actual difference
between each of the 11 leads and Lead II was calculated, the
QT interval was shorter in leads V3, V4 and V5 than in Lead II
(Table 1) and was longer than that in Lead II in the other 8
leads. However, when looking for the leadwith the QT interval
closest to that in Lead II, it does not matter if the difference is
positive or negative, what matters is that the absolute differ-
ence should be the least. We found the least absolute differ-
ence in QT intervals in aVR followed by aVF (Table 1). Lead V1,
aVL and Lead III showed the maximum difference. We found
that 6.9% of ECG had flat T waves in Lead II (Table 1). Of these,
the Twave amplitudewas also<1mm in lead aVR, aVF and V5
in 20% cases (1.4% of all 1906 ECGs). After excluding ECGs with
flat T waves, the absolute differences were the least with aVF
followed by aVR and highest in lead V1 (Table 1).
The mean T wave axis was 32 (SD 23) for all ECGs; it was
34 (SD 21, n ¼ 1773) for ECGs with Twave amplitude0.1mV
in Lead II and 5 (SD 34, n ¼ 133) for ECGs with T wave
amplitude <0.1 mV in Lead II.
As the leadwith the QT interval closest to Lead IImay differ
from individual to individual, we ranked the 11 leads based on
the absolute difference in QT interval between that lead and
Lead II in the 1906 ECGs; the lead with the least absolute
difference was ranked 1. Here too, the median rank was the
least for lead aVR and lead aVF (Table 1). Fig. 1 shows the
histograms of ranks of each of the individual 1906 ECGs. This
shows that the best alternative leads are aVR, aVF, V5, V6 and
V4. In 17.5% of ECGs, QT in lead aVRwas closest to that in Lead
II, while lead aVF was the closest in 17.4% of ECGs followed by
V4 (11.4%) and V5 (10.7%).4. Discussion
Our study showed that the QT interval was closest to Lead II in
lead aVR followed by aVF, and the precordial leads V5, V6 and
V4. TheQT interval in each of the 12 leads has been reported in
Table 1 e Difference in ms between QT intervals measured in each of the 11 leads from that in Lead II and medians and
interquartile ranges of ranks of each lead of the 1906 12-lead ECG. Ranks were assigned such that the lead with the QT
interval closest to that measured in Lead II (least absolute difference) was assigned Rank 1, while the one where it differed
maximally was assigned Rank 11.
Lead All ECGs ECGs with T wave amplitude  0.1 mV ECGs with T
amplitude
<0.1 mVaAbsolute
difference (ms)
Actual
difference (ms) Rank
Absolute
difference (ms)
Actual
difference (ms) Rank
Mean (99.5% CI) Mean (99.5% CI) Median (IQR) Mean (99.5% CI) Mean (99.5% CI) Median (IQR) %
I 13.0** (12.1, 14.0) 7.5** (6.3, 8.7) 5 (3, 7) 11.8** (10.9, 12.7) 7.3** (6.3, 8.4) 4 (3, 6) 8.97
III 18.5** (17.3, 19.6) 10.9** (9.4, 12.5) 6 (3, 8) 15.2** (13.7, 16.8) 11.3** (9.5, 13.2) 8 (7, 9) 54.93
AVR 8.7** (8.1, 9.4) 1.0** (0.2, 1.9) 3 (2, 5) 7.9** (7.4, 8.5) 0.9* (0.1, 1.6) 3 (2, 5) 6.45
AVF 9.1** (8.4, 9.8) 3.2** (2.3. 4.1) 3 (2, 5) 7.4** (6.9, 8.0) 3.4** (2.6, 4.1) 3 (1, 5) 26.86
AVL 22.1** (20.9, 23.3) 16.6** (15.0, 18.1) 7 (4, 8) 18.4** (16.9, 19.8) 14.1** (12.3, 15.9) 10 (9, 10) 47.32
V1 24.1** (22.8, 25.5) 18.4** (16.7, 20.1) 7 (4, 9) 23.4** (21.5, 25.3) 18.3** (16.0, 20.7) 8 (6, 9) 47.11
V2 14.4** (13.4, 15.5) 2.3** (0.9, 3.7) 5 (3, 7) 12.9** (11.9, 13.9) 0.6 (0.7, 1.9) 4 (2, 6) 7.61
V3 12.5** (11.6, 13.4) 3.2** (4.4, 2.0) 5 (3, 7) 11.5** (10.7, 12.2) 3.9** (5.0, 2.9) 4 (2, 6) 5.35
V4 11.5** (10.7, 12.3) 2.9** (4.1, 1.9) 4 (2, 6) 10.5** (9.8, 11.2) 3.6** (4.6, 2.6) 4 (2, 6) 5.04
V5 10.7** (9.8, 11.5) 1.2* (2.3, 0.1) 4 (2, 6) 9.6** (8.8, 10.4) 1.5** (2.5, 0.5) 4 (2, 5) 6.24
V6 10.9** (10.0, 11.7) 1.9** (0.9, 3.0) 4 (2, 6) 9.7** (9.0, 10.4) 1.8** (0.9, 2.7) 4 (2, 5) 9.34
Note: * <0.005; ** <0.001. CI: Confidence interval; IQR: Interquartile range.
a 6.9% of ECGs in Lead II had T wave amplitude <0.1 mV.
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and shortest QT intervals in different leads of the same ECG)
was considered a surrogate marker of dispersion of repolari-
zation in the ventricular myocardium.18e24 QT dispersion is
now rarely studied as it failed to be a reliable predictor of
proarrhythmia.14,25,26 Macfarlane et al studied effect of age on
QT dispersion in 1501 healthy normal volunteers. Although
the authors did not study this aspect, data from their paper
showed that the lead with mean actual QTc interval closest to
that in lead II (390.3  18.7 ms) was aVF (390.8  19.2 ms) fol-
lowed by lead V4 (389.9  17.9 ms).19 In the same study, the
leads which had QT interval farthest from lead II were lead I
(386.4  18.6 ms) and lead aVL (386.6  19.1 ms). Davey
analyzed his QT dispersion data differently; the QT interval in
lead II was correlated with QT interval in each of other 11
leads, the highest correlation coefficient (r ¼ 0.81) was ob-
tained with lead aVF.22 In another study, Sadanaga et al
studied QT dispersion in healthy Japanese subjects and
compared it with that in patients receiving psychotropic
drugs. As in our study, they too found that the mean QT
interval measurement closest to that in lead II (353  29 ms)
was observed in lead aVF (351  30 ms) while lead aVL had
a mean QT interval measurement farthest from lead II
(332  31 ms).20
Why is the QT interval in leads aVF or aVR closest to that in
Lead II? It was previously thought that the difference in QT
interval in various leads was due to transmural dispersion of
ventricular repolarization. However, subsequent studies show
that the QT interval in each lead depends on the direction of
the general T wave vector,27,28 projections of T wave vector
loops on the 12 leads of the ECG,29,30 distance between indi-
vidual leads and the heart,27 properties of intervening
tissues27 and electrical activity in the myocardium underlying
the precordial leads.27 The limb leads of the ECG are assumed
to be attached to the angles of the hypothetical Einthoven’s
triangle represented by the torso with the heart at its centre
(Fig. 2A). The six limb leads of the ECG are therefore orientedin a hex-axial reference system (Fig. 2B) with Lead II having an
axis of þ60. The leads with their axes closest to lead II are
Lead aVR (axisþ30) on one side and lead aVF (axisþ90) on
the other side. Not surprisingly, QT interval measurements
in these leads were the closest to those in Lead II in our study.
Schamroth recommends the use of lead aVL for QT interval
measurements as the U wave is usually isoelectric in this
lead, and it also has the earliest Q onset when compared
to other leads.7 However, we found that QT interval in Lead
aVL, which has its axis perpendicular (30) to that of Lead II,
differed maximally from that in Lead II.
One of the situationswhenQT intervalmay bemeasured in
an alternative lead is when T wave amplitude in Lead II is
<0.1 mV; this was found in 6.9% of ECGs in our study. Since T
wave amplitude depends on T wave axis, it may be possible
that the T wave amplitude in aVR, aVF or V5 may also be low
since the axes of these leads are close to that of Lead II.
However, we found that T wave amplitude was <0.1 mV in
Lead II as well as all three alternative leads in only 1.4% of
ECGs. Thus, it was possible to use these alternative leads in
more than 98% of all ECGs.
4.1. Limitations and strengths
Our study has one main limitation: a single ECG from each
subject was selected for evaluation. Whether a different lead
would have been superior in another ECG from the same
subject is debatable. On the other hand, use of digital ECGs
with high sampling rates, large number of subjects, and
measurement of intervals by experienced readers in a core
ECG lab are some of the strengths of our study.5. Conclusion
QT interval is commonly measured in Lead II. Our study
indicates that when the tracing in Lead II is of poor quality,
Fig. 2 e A) Position of T wave vector with respect to Einthoven’s triangle. B) Position of T wave vector with respect to hex-
axial system of leads.
Fig. 1 e Histograms of ranks assigned to each lead of 1906 ECGs. Ranks were assigned such that the lead with the QT
interval closest to that measured in Lead II was assigned Rank 1, while the one where it differed maximally was assigned
Rank 11. Lead aVR had the maximum number of ECGs with Rank 1 followed by aVF. Maximum ECGs with Ranks 10 and 11
were seen in lead aVL.
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a value closest to that in lead II. Since the QT interval in
a particular lead depends on the size and shape of the T wave,
which in turn is influenced largely by the direction of
the global T wave vector, Leads aVR and aVF, with their
axes closest to that of lead II, appear to be the best alternatives
to Lead II for QT interval measurement. Our study also
shows that Lead aVL should not be used for QT interval
measurements when baseline evaluations are performed in
lead II.Authors’ disclosures
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